森萱医药
(830946)
| 流通市值：31.62亿 | | | 总市值：31.63亿 |
| 流通股本：4.27亿 | | | 总股本：4.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 137,674,996.19 | 589,560,024.01 | 445,083,009.8 | 317,588,772.54 |
| 营业收入 | 137,674,996.19 | 589,560,024.01 | 445,083,009.8 | 317,588,772.54 |
| 二、营业总成本 | 97,935,912.87 | 427,327,950.06 | 321,419,605.37 | 223,979,453.94 |
| 营业成本 | 77,335,849.23 | 335,980,185.9 | 254,557,989.39 | 181,104,613.19 |
| 税金及附加 | 1,736,537.2 | 7,066,385.94 | 5,375,212.89 | 3,705,418.1 |
| 销售费用 | 3,612,552.15 | 15,074,846.21 | 11,823,480.36 | 7,429,897.6 |
| 管理费用 | 12,548,691 | 56,175,633.1 | 40,783,143.15 | 26,947,574.65 |
| 研发费用 | 7,116,442.26 | 28,177,102.17 | 21,290,297.26 | 14,018,463.24 |
| 财务费用 | -4,414,158.97 | -15,146,203.26 | -12,410,517.68 | -9,226,512.84 |
| 其中:利息费用 | 229,865.06 | 948,266.16 | 712,168.89 | 488,812.45 |
| 其中:利息收入 | 3,832,796.92 | 14,531,384.19 | 10,785,997.77 | 7,376,690.15 |
| 加:公允价值变动收益 | 1,011,969.86 | 3,044,254.79 | 2,312,394.51 | 1,529,534.24 |
| 加:投资收益 | -1,981.66 | 883,286.46 | 546,540.76 | 42,159.39 |
| 资产处置收益 | - | -66,240.84 | -66,240.84 | -66,240.84 |
| 资产减值损失(新) | 390,262.79 | -3,881,006.43 | -1,608,035.88 | -1,789,294.39 |
| 信用减值损失(新) | -405,558.81 | 1,524,093.98 | 513,435.07 | -618,410.26 |
| 其他收益 | 1,223,389.12 | 2,540,386.83 | 600,763.91 | 380,969.79 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 41,957,164.62 | 166,276,848.74 | 125,962,261.96 | 93,088,036.53 |
| 加:营业外收入 | 2,500.27 | 114,607.39 | 16,918.76 | 5,000 |
| 减:营业外支出 | 2,520 | 965,758.72 | 319,592.07 | 25,045 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 41,957,144.89 | 165,425,697.41 | 125,659,588.65 | 93,067,991.53 |
| 减:所得税费用 | 5,587,392.6 | 24,222,953.74 | 16,492,566.85 | 12,551,574.03 |
| 六、净利润 | 36,369,752.29 | 141,202,743.67 | 109,167,021.8 | 80,516,417.5 |
| 持续经营净利润 | 36,369,752.29 | 141,202,743.67 | 109,167,021.8 | 80,516,417.5 |
| 归属于母公司股东的净利润 | 34,861,755.22 | 134,523,788.78 | 103,319,227.37 | 76,632,214.85 |
| 少数股东损益 | 1,507,997.07 | 6,678,954.89 | 5,847,794.43 | 3,884,202.65 |
| (一)基本每股收益 | 0.08 | 0.32 | 0.24 | 0.18 |
| (二)稀释每股收益 | - | - | 0.24 | 0.18 |
| 九、综合收益总额 | 36,369,752.29 | 141,202,743.67 | 109,167,021.8 | 80,516,417.5 |
| 归属于母公司股东的综合收益总额 | 34,861,755.22 | 134,523,788.78 | 103,319,227.37 | 76,632,214.85 |
| 归属于少数股东的综合收益总额 | 1,507,997.07 | 6,678,954.89 | 5,847,794.43 | 3,884,202.65 |
| 公告日期 | 2024-04-29 | 2024-04-18 | 2023-10-27 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |